

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

EQUALITY IMPACT ASSESSMENT

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

Rheumatoid Arthritis

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

1.0 Scope: before consultation (To be completed by the developer and submitted with the draft scope for consultation)

1.1 Have any potential equality issues been identified during the development of the draft scope, before consultation, and, if so, what are they?

The pharmacological management of rheumatoid arthritis in women who are pregnant has been raised as a potential equality issue, as the pharmacological treatments for rheumatoid arthritis are contraindicated during pregnancy (due to toxicity) and therefore not licensed for this population.

1.2 What is the preliminary view on the extent to which these potential equality issues need addressing by the Committee? For example, if population groups, treatments or settings are excluded from the scope, are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

This issue was raised with stakeholders at the stakeholder workshop. It was agreed that this was a very specialist group, in which the main pharmacological treatments for rheumatoid arthritis were not licensed. It is anticipated that this may be addresses as a subgroup in the review questions of pharmacological treatments to enable separate recommendations to be made for this population.

Completed by Developer __Serena Carville_____

Date __08/06/16_____

Approved by NICE quality assurance lead __Christine Carson_____

Date __14/06/2016_____